Biotech Values

[DewDiligence]

THRX IPOs 11.5M* shares @$16.00:

https://www.prnewswire.com/news-releases/theseus-pharmaceuticals-announces-pricing-of-initial-public-offering-301394754.html

Theseus [Pharmaceuticals, Inc.] is a biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies. Theseus is developing next-generation tyrosine kinase inhibitors (TKIs): "pan-variant" targeted therapies that address all major drug resistance mutations. Theseus' lead product candidate, THE-630, is a pan-variant KIT inhibitor for the treatment of patients with advanced gastrointestinal stromal tumors (GIST), whose cancer has developed resistance to earlier lines of kinase inhibitor therapy. Theseus is also developing a fourth-generation, selective epidermal growth factor receptor (EGFR) inhibitor for C797S-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer (NSCLC).

*Assuming exercise of underwriter’s option.